OD260

OD260 is a specialized biotechnology company focused on the development and production of adenovirus vectors for gene therapy and vaccine research. The company provides a comprehensive suite of services including the construction, amplification, and purification of recombinant adenoviruses, as well as the supply of specialized reagents and cloning systems. Their proprietary AdenoQuick technology simplifies the generation of adenovirus vectors by utilizing Cre-loxP recombination, significantly reducing the time required for vector development. OD260 serves as a contract research organization (CRO) for academic and industrial partners globally, supporting early-stage research through to preclinical development. By focusing on high-titer, high-purity viral preparations, the company enables efficient gene delivery across various therapeutic applications.